Celldom

Based in San Carlos, California, Celldom develops a live single-cell biology platform for the high-throughput analysis of cellular morphology, phenotypes, and molecular profiles in real-time. The company utilizes a razor-and-blade business model to commercialize its proprietary CloneXplorer instruments alongside consumable silicon nanowell chips and artificial intelligence software. These integrated hardware systems allow biomedical researchers to process and analyze between 300,000 and 3,000,000 individual cells per experiment without relying on complex microfluidics. Celldom targets the oncology and immunology drug discovery sectors, securing financial backing from the NIH and NIGMS to support its operations and an intellectual property portfolio of four filed patents. To date, the enterprise has raised $2.5 million in total funding, which includes a recent $930,000 grant allocation to advance its precision medicine applications. Celldom was founded in 2016 by Benjamin Yellen and Kris Wood.

High-Level Overview

Celldom is a biotech company that develops advanced platforms for high-throughput single-cell analysis, integrating live cell biology with genomic sequencing and real-time imaging. Their core product suite includes a machine and consumable chips designed to isolate, culture, image, and sequence individual cells efficiently and cost-effectively. This technology serves researchers and pharmaceutical companies focused on cell-based therapy optimization, drug resistance screening, antibody discovery, and cell line development. Celldom’s platform enables simultaneous analysis of up to 100,000 cells per experiment, offering a faster, cheaper, and more comprehensive alternative to competitors like 10X Genomics and Berkeley Lights[1][2][4].

Origin Story

Celldom was co-founded by Benjamin Yellen, a mechanical engineering professor who transitioned to full-time CEO, and Kris Wood, a Professor of Cancer Biology at Duke University who serves as Chief Scientist. The company emerged from the vision of accelerating biological research with the speed and scale of semiconductor industry advances, aiming to revolutionize single-cell pharmacogenomics and drug screening. Early traction came from developing a microfluidic chip with thousands of chambers for single-cell isolation and live imaging, combined with AI-driven analysis software, positioning Celldom as a pioneer in massively parallel single-cell biology[1][3].

Core Differentiators

• Unique Product Model: Celldom employs a "razor and blade" approach, selling a machine alongside consumable silicon chips with 6,000+ microfluidic chambers for single-cell capture and analysis[1].
• High Throughput & Efficiency: Their platform can analyze over 100,000 cells in parallel, significantly outpacing traditional methods in speed and cost[1][4].
• Integrated Live Imaging & Genomics: Enables real-time observation of cell behavior, morphology, and molecular profiling over multiple days, unlike competitors who focus mainly on sequencing[1][4].
• AI-Driven Data Analysis: The Celldom Distiller software visualizes massive datasets, allowing users to track individual cells and their responses dynamically[2].
• Versatile Experimental Design: Supports co-cultures, drug treatments, and functional assays such as T-cell killing, under controlled environmental conditions[4].

Role in the Broader Tech Landscape

Celldom rides the growing trend of single-cell biology and precision medicine, where understanding cellular heterogeneity is critical for developing targeted therapies. The timing is favorable due to increasing demand for scalable, high-resolution cell analysis tools in biopharma and life sciences. Market forces such as the rise of cell and gene therapies, immuno-oncology, and AI-driven drug discovery amplify Celldom’s relevance. By enabling massively parallel single-cell pharmacogenomics, Celldom accelerates drug candidate screening and cell therapy optimization, influencing the broader ecosystem by pushing the boundaries of throughput, cost-efficiency, and data integration in cell biology research[1][3][4].

Quick Take & Future Outlook

Celldom is poised to expand its impact by refining its platform for broader adoption in pharmaceutical R&D and clinical applications. Future trends shaping its journey include advances in multi-omics, AI-powered analytics, and the increasing need for personalized medicine solutions. As Celldom scales, it may further disrupt traditional single-cell analysis paradigms by enabling unprecedented experimental throughput and real-time functional insights. Its influence is likely to grow as the biotech industry increasingly relies on high-throughput, integrated platforms to accelerate discovery and therapeutic development, fulfilling the vision of making biology as scalable and efficient as semiconductor manufacturing[1][3][4].